secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001370053-25-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q1 net loss $39.3M ($1.28/sh); rosnilimab Phase 2b RA data positive; $75M buyback authorized
--------------------------------------------------------------------------------

- Cash and investments $383M as of March 31, 2025, with cash runway through year-end 2027.
- Collaboration revenue $27.8M (up from $7.2M YoY), driven by Jemperli royalties and Vanda license.
- R&D expenses $41.2M, up from $37.0M YoY, primarily due to rosnilimab RA/UC and preclinical programs.
- Rosnilimab achieved highest-ever CDAI LDA response in 424-patient Phase 2b RA trial; six-month data surpassed competitors.
- Initial Phase 2 UC data for rosnilimab expected Q4 2025; GSK Jemperli $1B sales milestone still anticipated 2025/2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/0001370053-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000045/anab-20250505.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer